Checkpoint Therapeutics (CKPT) Competitors $3.75 +0.28 (+8.07%) (As of 11/22/2024 ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends CKPT vs. LPTX, CRMD, STOK, ALT, DNTH, OCS, IMNM, TRML, VECT, and CDXCShould you be buying Checkpoint Therapeutics stock or one of its competitors? The main competitors of Checkpoint Therapeutics include Leap Therapeutics (LPTX), CorMedix (CRMD), Stoke Therapeutics (STOK), Altimmune (ALT), Dianthus Therapeutics (DNTH), Oculis (OCS), Immunome (IMNM), Tourmaline Bio (TRML), VectivBio (VECT), and ChromaDex (CDXC). These companies are all part of the "pharmaceutical products" industry. Checkpoint Therapeutics vs. Leap Therapeutics CorMedix Stoke Therapeutics Altimmune Dianthus Therapeutics Oculis Immunome Tourmaline Bio VectivBio ChromaDex Checkpoint Therapeutics (NASDAQ:CKPT) and Leap Therapeutics (NASDAQ:LPTX) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, institutional ownership, risk, analyst recommendations, valuation, community ranking, dividends, profitability and media sentiment. Do insiders and institutionals hold more shares of CKPT or LPTX? 22.0% of Checkpoint Therapeutics shares are held by institutional investors. Comparatively, 30.5% of Leap Therapeutics shares are held by institutional investors. 2.1% of Checkpoint Therapeutics shares are held by insiders. Comparatively, 5.4% of Leap Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth. Do analysts prefer CKPT or LPTX? Checkpoint Therapeutics presently has a consensus price target of $12.00, indicating a potential upside of 220.00%. Leap Therapeutics has a consensus price target of $7.50, indicating a potential upside of 194.12%. Given Checkpoint Therapeutics' higher probable upside, equities analysts plainly believe Checkpoint Therapeutics is more favorable than Leap Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Checkpoint Therapeutics 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00Leap Therapeutics 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 3.00 Which has preferable valuation & earnings, CKPT or LPTX? Checkpoint Therapeutics has higher earnings, but lower revenue than Leap Therapeutics. Checkpoint Therapeutics is trading at a lower price-to-earnings ratio than Leap Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCheckpoint Therapeutics$100K1,831.13-$51.85M-$1.84-2.04Leap Therapeutics$1.50M65.14-$81.41M-$1.93-1.32 Which has more volatility & risk, CKPT or LPTX? Checkpoint Therapeutics has a beta of 1.23, indicating that its stock price is 23% more volatile than the S&P 500. Comparatively, Leap Therapeutics has a beta of 0.22, indicating that its stock price is 78% less volatile than the S&P 500. Does the MarketBeat Community favor CKPT or LPTX? Leap Therapeutics received 117 more outperform votes than Checkpoint Therapeutics when rated by MarketBeat users. Likewise, 68.94% of users gave Leap Therapeutics an outperform vote while only 66.92% of users gave Checkpoint Therapeutics an outperform vote. CompanyUnderperformOutperformCheckpoint TherapeuticsOutperform Votes17666.92% Underperform Votes8733.08% Leap TherapeuticsOutperform Votes29368.94% Underperform Votes13231.06% Is CKPT or LPTX more profitable? Checkpoint Therapeutics' return on equity of 0.00% beat Leap Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Checkpoint TherapeuticsN/A N/A -659.07% Leap Therapeutics N/A -116.24%-93.18% Does the media favor CKPT or LPTX? In the previous week, Checkpoint Therapeutics had 4 more articles in the media than Leap Therapeutics. MarketBeat recorded 5 mentions for Checkpoint Therapeutics and 1 mentions for Leap Therapeutics. Leap Therapeutics' average media sentiment score of 3.00 beat Checkpoint Therapeutics' score of -0.39 indicating that Leap Therapeutics is being referred to more favorably in the news media. Company Overall Sentiment Checkpoint Therapeutics Neutral Leap Therapeutics Very Positive SummaryLeap Therapeutics beats Checkpoint Therapeutics on 9 of the 16 factors compared between the two stocks. Ad Weiss RatingsTrump won. Buy this coin now.Juan Villaverde called the top and bottom of every crypto bull market since 2012. He believes Bitcoin will go to $150,000 — or more. But there’s one coin he thinks could go even higher.This could be his favorite coin. Get Checkpoint Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for CKPT and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CKPT vs. The Competition Export to ExcelMetricCheckpoint TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$183.11M$6.58B$5.21B$8.85BDividend YieldN/A8.14%5.53%4.08%P/E Ratio-2.0411.12100.1317.87Price / Sales1,831.13356.821,235.9386.14Price / CashN/A53.8241.0136.92Price / Book-14.4210.597.206.54Net Income-$51.85M$153.02M$119.62M$226.15M7 Day Performance9.33%3.96%2.12%3.77%1 Month Performance9.97%-6.71%-2.43%4.64%1 Year Performance79.43%33.04%34.52%29.18% Checkpoint Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CKPTCheckpoint Therapeutics3.3579 of 5 stars$3.75+8.1%$12.00+220.0%+79.4%$183.11M$100,000.00-2.0410LPTXLeap Therapeutics2.5491 of 5 stars$2.56-1.2%$7.50+193.0%-10.8%$65.54M$1.50M-1.3440Positive NewsCRMDCorMedix2.4926 of 5 stars$10.33-3.8%$15.20+47.1%+172.1%$626.82M$60,000.00-13.2630STOKStoke Therapeutics3.8589 of 5 stars$11.37+0.5%$20.83+83.2%+194.6%$602.27M$8.78M-5.41100ALTAltimmune1.6777 of 5 stars$8.44+4.8%$20.00+137.1%+239.1%$600.00M$430,000.00-5.4450DNTHDianthus Therapeutics1.3911 of 5 stars$20.27-2.4%$46.43+129.1%+96.7%$599.99M$2.83M-8.1180OCSOculis2.9028 of 5 stars$14.75-1.1%$29.20+98.0%+51.1%$597.38M$980,000.00-7.642IMNMImmunome1.8678 of 5 stars$9.51+1.9%$28.83+203.2%+23.7%$593.55M$14.02M-1.1740TRMLTourmaline Bio1.7418 of 5 stars$22.75-5.2%$65.00+185.7%+28.6%$583.31MN/A-8.0744VECTVectivBioN/A$16.85flatN/AN/A$573.24M$27.34M0.0030High Trading VolumeCDXCChromaDex3.8224 of 5 stars$7.62+1.6%$8.00+5.1%+413.1%$572.87M$91.67M761.50106 Related Companies and Tools Related Companies Leap Therapeutics Competitors CorMedix Competitors Stoke Therapeutics Competitors Altimmune Competitors Dianthus Therapeutics Competitors Oculis Competitors Immunome Competitors Tourmaline Bio Competitors VectivBio Competitors ChromaDex Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:CKPT) was last updated on 11/23/2024 by MarketBeat.com Staff From Our PartnersMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | SponsoredCrypto’s next big bull run?Juan Villaverde may be America’s top crypto expert. And he says something big is coming for crypto – on Nov...Weiss Ratings | Sponsored24/7 Automated Profits in CryptoThe 4th quarter of 2024 is shaping up to be one of the most explosive periods for crypto in recent memory. But...Crypto Swap Profits | SponsoredElon knows the truth, which is why they want him silencedElon Musk is one of mankind’s greatest innovators. But for all his visionary prowess and contributions to h...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Checkpoint Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Checkpoint Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
